Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor.
PD176067 is a reversible and selective inhibitor of fibroblast growth factor receptor tyrosine kinase, and was in preclinical development as an angiogenesis inhibitor for the treatment of solid tumors. A 14-day oral toxicity study of PD176067 in young female rats (7 weeks old) was conducted at doses of 2.5, 5, and 10 mg/kg/day (15, 30, and 60 mg/m(2), respectively). Skeletal changes, and vascular and soft tissue mineralization were observed as primary drug-related toxicities. To determine if these changes are specific to young, rapidly growing animals with increased vascular and osseous development, PD176067 was administered to mature (11 months old) rats. Female rats received PD176067 by gavage for 14 days at doses of 2.5, 5, and 10 mg/kg/day and necropsied on day 15. Clinical signs of toxicity were seen at > or =5 mg/kg and one death occurred at 10 mg/kg. Physeal dysplasia (distal femur, proximal tibia, sternum) occurred in all drug-treated animals and was characterized by dose-related increased thickness of the zones of chondrocyte proliferation and hypertrophy, and marked thickening of the zone of ossification. Cartilage hyperplasia was characterized by proliferation of chondrocytes along margins of the synchondrosis and subperiosteum of sternebrae. Serum phosphorus levels increased 47% and 166% at 5 and 10 mg/kg, respectively. Mineralization of cardiac myocytes, aorta, various arteries, renal tubules, and gastric mucosa and muscularis was seen at 10 mg/kg, and consistent with the presence of calcium-phosphorus deposition. Physeal changes occurred at similar plasma PD176067 exposures in young and mature rats (AUC > or = 4.83 microg.hr/mL). PD176067 produced morphologically similar lesions in young and adult rats.
Brown
Alan P
AP
Safety Sciences, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. alan.brown@pfizer.com
Courtney
Cynthia L
CL
King
Lena M
LM
Groom
Stephen C
SC
Graziano
Michael J
MJ
D000284:Administration, Oral; D000367:Age Factors; D020533:Angiogenesis Inhibitors / Q000633:toxicity*; D000818:Animals; D002114:Calcinosis / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D019902:Chondrocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000633:toxicity*; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000037:antagonists & inhibitors*; D006574:Heterocyclic Compounds, 2-Ring / Q000494:pharmacology*; D010009:Osteochondrodysplasias / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D018675:Toxicity Tests
D020533:Angiogenesis Inhibitors; D004791:Enzyme Inhibitors; D006574:Heterocyclic Compounds, 2-Ring; C503679:PD176067; D011725:Pyridines; D016220:Fibroblast Growth Factor 1; D020794:Receptor Protein-Tyrosine Kinases